BAYRY — Bayer A.G.
Is BAYRY overbought or oversold? Here is the current MarketMoodz read.
Bayer A.G. (BAYRY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $12.64. The rating moved from Overbought to Oversold on September 30, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$12.64
- Last changeMoved from Overbought to Oversold on September 30, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
See all oversold Healthcare stocks →
AI analysis
Analysis of Bayer A.G. (BAYRY): the company benefits from diversification across pharmaceuticals and crop science, providing stable revenue streams, but elevated leverage and legacy legal exposure constrain upside. Near-term catalysts include cost-savings realization, portfolio disposals and pipeline/regulatory readouts; however, drug-pricing policy risk and agricultural commodity cyclicality create meaningful downside scenarios. Given mixed sector dynamics and current market risk-off sentiment, expect limited conviction for a strong directional move absent clearer earnings beats or corporate actions.
Key factors
- Diversified business mix across pharmaceuticals, consumer health (historical), and crop science provides revenue resilience and multiple cash-flow streams.
- Material legacy liabilities and elevated leverage following prior large acquisitions continue to pressure balance-sheet flexibility and credit profile.
- Exposure to regulatory and policy shifts (drug-pricing negotiations, payer pressure) that can compress margins in patented and specialty medicines.
- Agriculture/crop-science exposure creates sensitivity to commodity cycles, weather and global trade conditions but also offers secular demand drivers for crop protection and seeds.
- Cost-savings programs, portfolio optimization and potential asset disposals materially influence near-term free cash flow and deleveraging trajectory.
- Current market risk-off tone and light volumes limit near-term upside absent clearer earnings or corporate action catalysts.
Risks
- Ongoing or future litigation and legacy claims (e.g., glyphosate-related litigation history) that could generate unpredictable cash outflows or reserves.
- Heightened drug-pricing scrutiny (Medicare negotiation and international pricing pressure) that could reduce realized prices for key pharmaceuticals.
- Integration and execution risk tied to prior acquisitions/divestitures, and the ability to convert announced savings into sustained margin improvement.
- Commodity and agricultural cyclical volatility impacting Crop Science revenue and margin profiles.
- Foreign-exchange volatility and geopolitical disruptions affecting global supply chains and international sales.
- Clinical or regulatory setbacks for key pipeline assets or negative trial readouts that affect future revenue growth.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for BAYRY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.